vs
CASELLA WASTE SYSTEMS INC（CWST）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CASELLA WASTE SYSTEMS INC的1.6倍（$772.1M vs $469.1M），Revvity净利率更高（12.7% vs -0.5%，领先13.3%），CASELLA WASTE SYSTEMS INC同比增速更快（9.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $39.3M），过去两年CASELLA WASTE SYSTEMS INC的营收复合增速更高（17.3% vs 9.0%）
Casella Waste Systems Inc.是总部位于美国佛蒙特州拉特兰的废弃物管理企业，1975年创立时仅靠一辆卡车起步，现为区域型垂直一体化固体废物服务提供商，面向住宅、商业、市政及工业客户提供固废收集处置、中转、回收、有机废弃物处理等专业资源管理服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CWST vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$469.1M
营收增速更快
CWST
高出3.9%
5.9%
净利率更高
RVTY
高出13.3%
-0.5%
自由现金流更多
RVTY
多$122.5M
$39.3M
两年增速更快
CWST
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $469.1M | $772.1M |
| 净利润 | $-2.5M | $98.4M |
| 毛利率 | 33.3% | — |
| 营业利润率 | 2.5% | 14.5% |
| 净利率 | -0.5% | 12.7% |
| 营收同比 | 9.7% | 5.9% |
| 净利润同比 | -151.5% | 3.9% |
| 每股收益（稀释后） | $-0.04 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CWSTRVTY
| Q4 25 | $469.1M | $772.1M | ||
| Q3 25 | $485.4M | $698.9M | ||
| Q2 25 | $465.3M | $720.3M | ||
| Q1 25 | $417.1M | $664.8M | ||
| Q4 24 | $427.5M | $729.4M | ||
| Q3 24 | $411.6M | $684.0M | ||
| Q2 24 | $377.2M | $691.7M | ||
| Q1 24 | $341.0M | $649.9M |
净利润CWSTRVTY
| Q4 25 | $-2.5M | $98.4M | ||
| Q3 25 | $10.0M | $46.7M | ||
| Q2 25 | $5.2M | $53.9M | ||
| Q1 25 | $-4.8M | $42.2M | ||
| Q4 24 | $4.9M | $94.6M | ||
| Q3 24 | $5.8M | $94.4M | ||
| Q2 24 | $7.0M | $55.4M | ||
| Q1 24 | $-4.1M | $26.0M |
毛利率CWSTRVTY
| Q4 25 | 33.3% | — | ||
| Q3 25 | 35.0% | 53.6% | ||
| Q2 25 | 33.8% | 54.5% | ||
| Q1 25 | 32.8% | 56.5% | ||
| Q4 24 | 33.2% | — | ||
| Q3 24 | 35.1% | 56.3% | ||
| Q2 24 | 35.4% | 55.7% | ||
| Q1 24 | 32.3% | 54.6% |
营业利润率CWSTRVTY
| Q4 25 | 2.5% | 14.5% | ||
| Q3 25 | 6.1% | 11.7% | ||
| Q2 25 | 4.1% | 12.6% | ||
| Q1 25 | 0.8% | 10.9% | ||
| Q4 24 | 4.3% | 16.3% | ||
| Q3 24 | 5.9% | 14.3% | ||
| Q2 24 | 6.1% | 12.4% | ||
| Q1 24 | 2.0% | 6.8% |
净利率CWSTRVTY
| Q4 25 | -0.5% | 12.7% | ||
| Q3 25 | 2.1% | 6.7% | ||
| Q2 25 | 1.1% | 7.5% | ||
| Q1 25 | -1.2% | 6.4% | ||
| Q4 24 | 1.1% | 13.0% | ||
| Q3 24 | 1.4% | 13.8% | ||
| Q2 24 | 1.9% | 8.0% | ||
| Q1 24 | -1.2% | 4.0% |
每股收益（稀释后）CWSTRVTY
| Q4 25 | $-0.04 | $0.86 | ||
| Q3 25 | $0.16 | $0.40 | ||
| Q2 25 | $0.08 | $0.46 | ||
| Q1 25 | $-0.08 | $0.35 | ||
| Q4 24 | $0.08 | $0.77 | ||
| Q3 24 | $0.10 | $0.77 | ||
| Q2 24 | $0.12 | $0.45 | ||
| Q1 24 | $-0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $123.8M | $919.9M |
| 总债务越低越好 | $1.1B | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $3.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资CWSTRVTY
| Q4 25 | $123.8M | $919.9M | ||
| Q3 25 | $192.7M | $931.4M | ||
| Q2 25 | $217.8M | $991.8M | ||
| Q1 25 | $267.7M | $1.1B | ||
| Q4 24 | $358.3M | $1.2B | ||
| Q3 24 | $519.0M | $1.2B | ||
| Q2 24 | $208.5M | $2.0B | ||
| Q1 24 | $189.5M | $1.7B |
总债务CWSTRVTY
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $976.6M | — | ||
| Q1 24 | $980.9M | — |
股东权益CWSTRVTY
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.5B | $7.9B | ||
| Q2 24 | $1.0B | $7.9B | ||
| Q1 24 | $1.0B | $7.8B |
总资产CWSTRVTY
| Q4 25 | $3.3B | $12.2B | ||
| Q3 25 | $3.3B | $12.1B | ||
| Q2 25 | $3.3B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.2B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
负债/权益比CWSTRVTY
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | 0.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $96.6M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $39.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.4% | 21.0% |
| 资本支出强度资本支出/营收 | 12.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $84.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CWSTRVTY
| Q4 25 | $96.6M | $182.0M | ||
| Q3 25 | $93.6M | $138.5M | ||
| Q2 25 | $89.5M | $134.3M | ||
| Q1 25 | $50.1M | $128.2M | ||
| Q4 24 | $109.8M | $174.2M | ||
| Q3 24 | $91.8M | $147.9M | ||
| Q2 24 | $72.1M | $158.6M | ||
| Q1 24 | $7.7M | $147.6M |
自由现金流CWSTRVTY
| Q4 25 | $39.3M | $161.8M | ||
| Q3 25 | $27.6M | $120.0M | ||
| Q2 25 | $23.1M | $115.5M | ||
| Q1 25 | $-5.4M | $112.2M | ||
| Q4 24 | $32.9M | $149.8M | ||
| Q3 24 | $40.4M | $125.6M | ||
| Q2 24 | $27.5M | $136.6M | ||
| Q1 24 | $-22.6M | $129.7M |
自由现金流率CWSTRVTY
| Q4 25 | 8.4% | 21.0% | ||
| Q3 25 | 5.7% | 17.2% | ||
| Q2 25 | 5.0% | 16.0% | ||
| Q1 25 | -1.3% | 16.9% | ||
| Q4 24 | 7.7% | 20.5% | ||
| Q3 24 | 9.8% | 18.4% | ||
| Q2 24 | 7.3% | 19.7% | ||
| Q1 24 | -6.6% | 20.0% |
资本支出强度CWSTRVTY
| Q4 25 | 12.2% | 2.6% | ||
| Q3 25 | 13.6% | 2.6% | ||
| Q2 25 | 14.3% | 2.6% | ||
| Q1 25 | 13.3% | 2.4% | ||
| Q4 24 | 18.0% | 3.4% | ||
| Q3 24 | 12.5% | 3.3% | ||
| Q2 24 | 11.8% | 3.2% | ||
| Q1 24 | 8.9% | 2.7% |
现金转化率CWSTRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 9.37× | 2.97× | ||
| Q2 25 | 17.19× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 22.51× | 1.84× | ||
| Q3 24 | 15.91× | 1.57× | ||
| Q2 24 | 10.29× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CWST
| Transferred Over Time | $120.9M | 26% |
| Resource Solutions Region | $92.9M | 20% |
| Collection | $90.9M | 19% |
| Mid Atlantic Region | $89.6M | 19% |
| National Accounts | $60.9M | 13% |
| Landfill Revenue | $8.3M | 2% |
| Processing Services | $2.1M | 0% |
| Transportation | $1.4M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
